Geert Mayer, MD: Safety, Efficacy of Solriamfetol for Excessive Sleepiness In Narcolepsy, OSA

“I think it [solriamfetol] does a great reduction and the number of patients who are responders is extremely high."

Over the years, sleep medicine has undergone a great deal of advancement in therapeutics, but one disorder particularly lacking good, safe and effective treatments is excessive sleepiness with narcolepsy or obstructive sleep apnea. Solriamfetol, a dopamine and norepinephrine reuptake inhibitor with wake-promoting effects, is one such entity under investigation. In March, the FDA accepted an application for solriamfetol as a treatment for excessive sleepiness associated with narcolepsy or obstructive sleep apnea and has a PDUFA action date set for Dec. 20, 2018.

At the 24^th Congress of European Sleep Research Society in Basel, Switzerland, Geert Mayer, MD, neurologist and sleep specialist, Philipps University of Marburg, sat down with NeurologyLive to discuss the results of a long-term study observing the safety and maintenance of efficacy of solriamfetol (JZP-110) for treatment of excessive sleepiness associated with narcolepsy or obstructive sleep apnea.

Mayer noted that the study proved solriamfetol, an additional wake-promoting agent, to be an efficacious medication that has good safety and long-term data and does not impact nighttime sleep. Long-term maintenance of efficacy was demonstrated after 1 year of treatment and the safety profile was consistent with prior placebo-controlled studies.

Future studies, Mayer concluded, need to be conducted to best determine long-term data and determine if the safety profile stays the same in say 5 or 10 years. Additionally, Mayer suggested that solriamfetol could possibly be used in other fields of excessive daytime sleepiness or even perhaps other neurodegenerative disorders.